 |
|
|
| |
Raltegravir 96 Weeks data from Phase II Study in Treatment-Naive
|
| |
| |
Reported by Jules Levin
Police presence by my hotel
Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 96-week data
M. Markowitz1, B.-Y. Nguyen2, E. Gotuzzo3, F. Mendo4, W. Ratanasuwan5, C. Kovacs6, H. Wan2, H. Campbell2, M. Miller2, R. Isaacs2, H. Teppler2, and the Protocol 004 Part II Study Team
1Aaron Diamond AIDS Research Center, New York, NY; 2Merck Research Labs, West Point, PA; 3Hospital Nacionale Cayetano Heredia, Lima, Peru; 4Hospital Nacionale Edgardo Rebagliati, Lima, Peru; 6Maple Leaf Medical Center, Toronto, Canada; 5Siriraj Hospital, Bangkok, Thailand
AUTHOR CONCLUSIONS
At 96 weeks, RAL had sustained antiretroviral effect similar to 48 week data and to EFV (both with TDF/3TC)
--83% vs 84% (RAL vs EFV) with HIV RNA < 50 copies/mL
-- No new RAL mutations identified after 48 weeks
RAL was generally well tolerated at 96 weeks:
-- Drug-related AEs appeared less frequent for RAL vs. EFV
-- RAL had neutral effect on total cholesterol, LDL-C, and triglycerides.
SEE LIPIDS PROFILE BELOW
|
| |
|
|
|
|
|
